The collaboration with GC4K positions Charles River Laboratories at the forefront of gene therapy manufacturing for rare diseases, which could enhance its reputation and potentially lead to increased demand for its services. The specific mention of its eXpDNA™ platform and the recent opening of its HQ Plasmid Manufacturing Center of Excellence highlight the company's commitment to this area, which may be viewed positively by investors. The news could lead to a short-term positive impact on the stock price as the market reacts to the potential for future growth in this high-value sector.